The Searle Company Limited has successfully obtained regulatory approval from Pakistan's Drug Regulatory Authority (DRAP) for biosimilar Denosumab injections in 60mg and 120mg formulations, marking a significant milestone in the company's product portfolio expansion.
The pharmaceutical company announced the regulatory achievement through a notice to the Pakistan Stock Exchange on Monday, in accordance with Section 96 of the Securities Act, 2015 and Clause 5.6.1(a) of the PSX Rule Book.
Licensing Partnership and Market Rights
Under a licensing agreement with Mabwell Pharmaceuticals of China, Searle has been granted exclusive rights as the product registration holder to market and sell these biosimilar drugs throughout Pakistan. The Chinese company serves as the manufacturer for both formulations.
Therapeutic Applications
The approved Denosumab biosimilars target two distinct therapeutic areas. The 60mg formulation is indicated for osteoporosis management, while the 120mg dose is designed for oncology care applications. Denosumab functions as a monoclonal antibody, representing an important therapeutic option in both bone health and cancer treatment protocols.
Commercial Launch Preparations
Searle is currently preparing for the commercial launch of both Denosumab injection formulations in the Pakistani market. The company views this development as a key step in strengthening its business operations and enhancing the quality of its earnings profile.
According to the company's filing, this regulatory approval reflects Searle's commitment to expanding its therapeutic offerings and creating greater value for shareholders through strategic product portfolio diversification. The successful registration positions the company to address unmet medical needs in both osteoporosis management and oncology care within Pakistan's healthcare system.
